US FTC orders Illumina to divest cancer detection test maker Grail
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Illumina (ILMN) to appeal FTC decision ordering the unwinding of GRAIL deal
April 3, 2023 12:03 PM EDTIllumina (NASDAQ: ILMN) will appeal the Federal Trade Commission's (FTC) decision to order the unwinding of Illumina's $7.1 billion acquisition of GRAIL, the company announced.
The FTC issued an Opinion and Order on Monday, requiring the DNA sequencing provider to divest GRAIL, stating that the deal would stifle competition and innovation in the U.S. market for life-saving cancer tests.
The decision by the FTC reverses an administrative... More
